NSAID-induced gastrointestinal damage - Epidemiology, risk and prevention, with an evaluation of the role of misoprostol. An Asia-Pacific perspective and consensus

Drugs

Volumn 53, Issue 1, 1997, Pages 6-19

  Champion, G David ^a   Feng, Pao Hsii ^b   Azuma, Takeshi ^c   Caughey, David E ^d   Chan, Ka Ho ^e   Kashiwazaki, Sadao ^f   Liu, Hwa Chang ^g   Nasution, Achmad R ^h   Nobunaga, Masashi ⁱ   Prichanond, Surawut ^j   Torralba, Tito P ^k   Udom, Visitsunthorn ^l   Utis, Deesomchok ^m   Wang, Soo Ray ⁿ   Wong, Woon Sing ^o   Yang, Dah Jung ⁿ   Yoo, Myung Chul ^p  

^a ST VINCENT'S CLINIC   (Australia)

^b TAN TOCK SENG HOSPITAL   (Singapore)

^c Toyoko Hospital   (Japan)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e New World Towers   (Hong Kong)

^f TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^h UNIVERSITY OF INDONESIA   (Indonesia)

ⁱ KYUSHU UNIVERSITY   (Japan)

^j Vichaiyudh Hospital   (Thailand)

^k UNIVERSITY OF SANTO TOMAS HOSPITAL   (Philippines)

^l Payathai I Hospital   (Thailand)

^m KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

ⁿ TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^o QUEEN MARY HOSPITAL   (Hong Kong)

^p Kyung Hee University College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CAPSAICIN; DICLOFENAC; HISTAMINE H2 RECEPTOR ANTAGONIST; IBUPROFEN; INDOMETACIN; MECLOFENAMIC ACID; MISOPROSTOL; NABUMETONE; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PROSTAGLANDIN; RANITIDINE; SALICYLIC ACID; SUCRALFATE;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DUODENUM ULCER; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; META ANALYSIS; ORAL DRUG ADMINISTRATION; OSTEOARTHRITIS; PRACTICE GUIDELINE; PRESCRIPTION; PROSTAGLANDIN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; RISK; STOMACH ULCER; TOPICAL DRUG ADMINISTRATION;

EID: 0344798192     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199753010-00002     Document Type: Review

References (112)

1. Gibson T. Nonsteroidal anti-inflammatory drugs: another look. Br J Rheumatol 1984; 27: 87-40
2. Baum C, Kennedy DL, Forbes MB. Utilization of nonsteroidal anti-inflammatory drugs. Arthritis Rheum 1985; 28: 686-92
3. Simon LS. Actions and toxicity of nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1995; 7: 159-66
4. Roth SH, Fries JF, Abadi IA, et al. Prophylaxis of nonsteroidal antiinflammatory drug gastropathy: a clinical opinion. J Rheumatol 1991; 18: 956-8
5. Andrianakos A, Avouac B, Bijlsma JWJ, et al. Prevention of non-steroidal anti-inflammatory drug (NSAID) induced gastropathy. Eur J Rheum Inflamm 1992; 12 (3): 23-9
6. Data from Datamonitor, London, 1994
7. Data on file, Arthritis Foundation of New Zealand
8. Delmas PD. A review of the current use of anti-inflammatories. In: Nasution AR, Darmawan J, Isbagio H, editors. Proceedings of the 7th APLAR Congress of Rheumatology; 1992 Sep 13-18; Bali. Tokyo: Churchill Livingstone, 1992: 337
9. Haslock I. Review of induced upper gastrointestinal morbidity and mortality. In: Cheli R, editor. Treatment and prevention of NSAID-induced gastropathy. Royal Society of Medicine Services International Congress and Symposium Series 1989; 147: 3-10
10. Prichard P, editor. Non-steroidal anti-inflammatory drugs (NSAIDs) and the upper gut: an information booklet for health care providers. Australian Gastroenterology Institute, Arthritis Foundation of Australia and Australian Rheumatology Association, 1992
11. Day RO, Henry DA, Muirden KD, et al. Non-steroidal anti-inflammatory drug induced gastrointestinal hemorrhage and bleeding. Med J Aust 1992; 157: 810-2
12. Johnson AG, Quinn DI, Day RO. Non-steroidal anti-inflammatory drugs. Med J Aust 1995; 163: 155-8
13. McManus P, Primrose JG, Henry DA, et al. Pattern of non-steroidal anti-inflammatory drug use in Australia 1990-1994: a report from the Drug Utilization Sub-Committee of the Pharmaceutical Benefits Advisory Committee. Med J Aust 1996; 164: 589-92
14. Griffin JP. Survey of the spontaneous adverse drug reaction reporting schemes in fifteen countries. Br J Clin Pharm 1986; 22: 83S-100S
15. Committee on Safety of Medicines: CSM update. Nonsteroidal anti-inflammatory drugs and serious gastrointestinal adverse reactions: 2. BMJ 1986; 292: 1190-1
16. Geis GS, Stead H, Wallemark C-B, et al. Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAIDs in patients with RA or OA, and interim report on prevention by misoprostol of diclofenac-associated lesions. J Rheumatol 1991; 18 Suppl. 28: 11-4
17. Nobunaga M. NSAID-induced GI damage: a serious problem? In: Nasution AR, Darmawan J, Isbagio, editors. Proceedings of the 7th APLAR Congress of Rheumatology: 1992 Sep 13-18; Bali. Tokyo: Churchill Livingstone, 1991: 319
18. Larkai EN, Smith JL, Lidsky, et al. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic non-steroidal anti-inflammatory drug use. Am J Gastroenterol 1987; 82: 1153-8
19. Sontag S, Schnell T, Mak E, et al. NSAIDs with or without prednisone: bad news for the gut mucosa [abstract]. Gastroenterology 1989; 96: A483
20. Semble EL, Turner RA, Wu WC. Clinical and genetic characteristics of upper gastrointestinal disease in rheumatoid arthritis. J Rheumatol 1987; 14: 692-9
21. Morris AD, Holt SD, Silvoso GR, et al. Effect of anti-inflammatory drug administration in patients with rheumatoid arthritis: an endoscopic assessment. Scand J Gastroenterol 1981; 67 Suppl.: 131-5
22. Stark MT, Lewis JH. Over the counter NSAIDs are just as likely to cause acute upper gastrointestinal bleeding as are prescription NSAIDs [abstract]. Am J Gastroenterol 1990; 85: 1236
23. Collins AJ. NSAID-induced small and large bowel damage. New Standards in Arthritis Care 1991; 2 (2): 2-5
24. Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992; 327: 749-54
25. Fries JF. NSAID gastropathy: epidemiology. J Musculoskel Med 1991; 8 (2): 21-8
26. Barrier CH, Hirschowitz BI. Controversies in the detection and management of nonsteroidal anti-inflammatory drug-induced side effects of the upper gastrointestinal tract. Arthritis Rheum 1989; 32: 926-32
27. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987; 28: 527-32
28. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med 1988; 109: 359-63
29. Beardon PHG, Brown SV, McDevitt DG. Gastrointestinal events in patients prescribed nonsteroidal anti-inflammatory drugs: a controlled study using record linkage in Tayside. Q J Med 1989; 71: 497-505
30. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991; 114: 257-63
31. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammaiory drugs: a meta-analysis. Ann Intern Med 1991; 115: 787-96
32. Freston MS, Freston JW. Peptic ulcers in the elderly: unique features and management. Geriatrics 1990; 45: 39-45
33. Schedule of Pharmaceutical Benefits. Pharmaceutical Benefits Advisory Committee, Australia; Dec 1, 1992
34. Silvoso GR, Ivey KJ, Butt JH, et al. Incidence of gastric lesions in patients with rheumatic disease on chronic aspirin therapy. Ann Intern Med 1979; 91: 517-20
35. Caruso I, Bianchi Porro G. Gastroscopic evaluation of anti-inflammatory agents. BMJ 1980; 280: 75-8
36. Farah D, Sturrock RD, Russell RI. Peptic ulcers in rheumatoid arthritis. Ann Intern Med 1988; 47: 472-80
37. Shiokawa Y, Nobunaga M, Saito N, et al. Epidemiology study of upper GI tract lesions induced by NSAIDs. Ryumachi 1991; 31: 96-111
38. Shallcross TM, Heatley RV. Effect of non-steroidal anti-inflammatory drugs on dyspeptic symptoms. BMJ 1990; 300: 568-9
39. Skander MP, Ryan FP. Nonsteroidal anti-inflammatory drugs and pain-free peptic ulceration in the elderly. BMJ 1988; 297: 833-4
40. Laporte JR, Carne X, Vidal X, et al. Upper gastrointestinal bleeding in relation to previous ulse of analgesics and non-steroidal anti-inflammatory drugs. Lancet 1991; 337: 85-9
41. Langman MJS, Well J, Wright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075-8
42. Carson JL, Strom BL, Soper KA, et al. The association of non-steroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med 1987; 144: 85-8
43. Rossi SC, Hsu JP, Faich CA. Ulcerogenicity of piroxicam: an analysis of spontaneously reported data. BMJ 1987; 294: 147-50
44. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 10: 1078-88
45. Garcia Rodriguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 769-72
46. Singh G, Ramey DR, Morefeld, et al. Comparative toxicity of non-steroidal anti-inflammatory agents. Pharmacol Ther 1994; 62: 175-91
47. Mitchell JA, Akarasereenont P, Thiemermann C, et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1994; 90: 11693-7
48. Vane J. Toward a better aspirin. Nature 1994; 367: 215-6
49. Huyllar J, Bjarnason I. NSAIDs. Cox-2 inhibitors, and the gut. Lancet 1995; 346: 521-2
50. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-5
51. Semble EL, Wu WC. Prostaglandins in the gut and their relationship to nonsteroidal anti-inflammatory drugs. Baillieres Clin Rheumatol 1989; 3: 247-69
52. Hawkey CJ. Nonsteroidal anti-inflammatory drugs and the gastric mucosa: mechanisms of damage and protection. Aliment Pharmacol Ther 1988; 2 Suppl. 1: 57-64
53. Fromm D. Mechanisms involved in gastric mucosal resistance to injury. Ann Rev Med 1987; 38: 119-28
54. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol 1983; 245: G601-23
55. Soll AH. Review: antisecretory drugs: cellular mechanisms of action. Aliment Pharmacol Ther 1987; 1: 77-89
56. Cohen MM. Role of endogenous prostaglandins in gastric secretion and mucosal defense. Clin Invest Med 1987; 10: 226-31
57. Decker R, Peller T, Nguyen I, et al. Are liquid NSAIDs less ulcerogenic than solid NSAIDs in the stomach? Gastroenterol 1992; 102 (4 Pt 2): A567
58. Lanza FL, Karlin DA, Yee JP. A double-blind placebo controlled endoscopic study comparing the mucosal injury seen with orally and parenterally administered nonsteroidal analgesic ketorolac thromethamine at therapeutic and supratherapeutic doses [abstract]. Am J Gastroenterol 1987; 82: 939
59. Trondstad R, Bell H, Holler T. Endoscopic evaluation of the effect of naproxen tablets and suppositories on the gastric mucosa in healthy volunteers [abstract]. Endoscopy 1988; 20: 58
60. Berry H, Swinson D, Jones H, et al. Indomethacin and naproxen suppositories in the treatment of rheumatoid arthritis. Ann Rheum Dis 1978; 37: 370-2
61. Lanza FL, Royer GL, Nelson RS. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 1980; 303: 136-8
62. Graham DY. The relationship between non-steroidal anti-inflammatory drug use and peptic ulcer disease. Gastroenterol Clin North Am 1990; 19: 171-82
63. Graham DY. NSAID gastroduodenal injury: a clinical dilemma in arthritis care. New Standards in Arthritis Care 1990; 1 (1): 2-5
64. Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89 Suppl.: S116-28
65. Roth SA, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy: recognition and response. Arch Intern Med 1987; 147: 2093-100
66. Peltier AP. Practical management of NSAID gastropathy in rheumatic patients. Scand J Rheumatol 1989; 78: 12-7
67. Soll AH, Kurata J, McGuigan JE. Ulcers, nonsteroidal anti-inflammatory drugs, and related matters. Gastroenterology 1989; 96: 561-8
68. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991; 114: 735-40
69. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 1941; 91: 213-22
70. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduced serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs: a randomized, double-blind placebo-controlled trial. Ann Intern Med 1995; 123: 241-9
71. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal complications of non-steroidal anti-inflammatory drug treatment in rheumatoid arthritis: a prospective observational cohort study. Arch Intern Med 1996; 156: 1530-6
72. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis: Pt 1. Osteoarthritis of the hip. Arthritis Rheum 1995; 38: 1535-40
73. Hochberg MC, Altman RD, Brandt KD, et al. Guidelines for the medical management of osteoarthritis: Pt II. Osteoarthritis of the knee. Arthritis Rheum 1995; 38: 1541-6
74. Dewitt DL, Smith WL. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence. Proc Natl Acad Sci USA 1988; 985: 1412-6
75. Meade EA, Smith WL, Dewitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isoenzymes by aspirin and other nonsteroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610-4
76. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological charaterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther 1994; 217: 1705-12
77. Roth SH, Tindall EA, Jain AK, et al. A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract. Arch Intern Med 1993; 153: 2565-71
78. Ehsanullah RSB, Page MC, Tildesley G, et al. Prevention of gastroduodenal damage induced by nonsteroidal anti-inflammatory drugs: controlled trial with ranitidine. BMJ 1988; 297: 1017-21
79. Robinson MG, Griffin JW, Bowers J. Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal anti-inflammatory drugs. Dig Dis Sci 1989; 34: 424-8
80. Taha AS, Hudson N, Hawkey CJ, et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal ant-inflammatory drugs. N Engl J Med 1996; 334: 1435-9
81. Bigard MA. Complete prevention by omeprazole of aspirin induced gastric lesions in healthy subjects [abstract]. Gastroenterology 1988; 94: A34
82. Muller VP, Dammann HG, Simon B. Akute Schädigung der Magenschleimhaut durch Acetylsalicylsäure: eine endoskopische Vergleichsstudie am Menschen mit oral wirksamen Prostaglandin-analoga, Omeprazol und Ranitidin [abstract]. Arzneimittelforschung 1986; 36: 265
83. Oddsson E, Gudjonsson H, Thjodleifsson B. Protective effect of omeprazole or ranitidine against naproxen induced damage to the human gastroduodenal mucosa [abstract]. Scand J Gastroenterol 1990; 25 Suppl. 176: 25
84. Stern IA, Ward F, Hartley G. Protective effect of sucralfate against aspirin-induced damage to the human gastric mucosa. Am J Med 1987; 83 Suppl. 3B: 83-5
85. Wu WC, Castell DO. Does sucralfate protect against aspirin-induced mucosal lesions? Yes and no! [abstract]. Gastroenterology 1984; 86: 1303
86. Gudjonsson H, Oddsson E, Thjodleifsson B. Protective effect of sucralfate against naproxen induced damage to the human gastroduodenal mucosa [abstract]. Scand J Gastroenterol 1990; 25 Suppl. 176: 12
87. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer: a randomized, controlled trial. Ann Intern Med 1991; 115: 195-200
88. Graham DY, Agrawal NM, Roth SH. Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 1988; 11: 1277-80
89. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119: 257-62
90. Saito T. Misoprostol evaluated: the Japanese experience - results from misoprostol mucosal protection study. In: Nasution AR, Darmawan J, Isbagio, editors. Proceedings of the 7th APLAR Congress of Rheumatology: 1992 Sep 13-18; Bali. Tokyo: Churchill Livingstone, 1992: 327-9
91. Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: a prospective, double-blind, multicenter study. Am J Gastroenterol 1996; 91 (2): 223-7
92. Valentini M, Cannizzaro R, Poletti M, et al. Nonsteroidal anti-inflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. J Clin Oncol 1995; 13: 2637-42
93. Elliott SL, Yeomans ND, Buchanan RR, et al. Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers: a placebo-controlled trial. Scand J Rheumatol 1994; 23: 171-6
94. Agrawal NM, Van Kerckhove HE, Erhardt LJ, et al. Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers: a one-year study. Dig Dis Sci 1995; 40: 1125-31
95. Dajuni EZ, Wilson DE, Agrawal NM. Prostaglandins: an overview of the worldwide clinical experience. J Assoc Acad Minor Phys 1991; 2 (1): 23, 27-35
96. Inman WHW, editor. Drug Safety Research Unit (Southampton). PEM News 1991; 7: 32-4
97. Raskin JB, White RH, Jackson JE, et al. Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 1995; 123: 344-50
98. Walt RP. Misoprostol for the treatment of peptic ulcer and anti-inflammatory-drug-induced gastroduodenal ulceration. N Engl J Med 1992; 327: 1575-80
99. Medical Research Council Working Party. MRC trial of treatment of mild hypertension. BMJ 1985; 291: 97-104
100. Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results. JAMA 1984; 251: 351-74
101. Simon LS, Polisson RP, Hatoum HT, et al. Risk factors for serious nonsteroidal induced GI complications: the risk reduction effect of misoprostol therapy in the individual 'at-risk' patient [abstract]. Arthritis Rheum 1995; 38 Suppl.: S206
102. Bloom BS. Direct medical costs of disease and gastrointestinal side effects during treatment of arthritis. Am J Med 1988; 84 Suppl. 2A: 20-4
103. Bloom BS. Cost of treating arthritis and NSAID-related gastrointestinal side-effects. Aliment Pharmacol Ther 1988; 2 Suppl. 1: 131-9
104. Knill-Jones R, Drummond M, Kohli H, et al. Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs. Postgrad Med J 1990; 66: 639-46
105. Hillman AL, Bloom BS. Economic effects of prophylactic use of misoprostol drugs. Arch Intern Med 1989; 149: 2061-5
106. de Pouvourville G, Bader JP. Analyse économique du traitement préventif par le misoprostol chez l'homme des ulcères gastriques liés auz anti-inflammatoires non-stéröidiens. Gastroenterol Clin Biol 1991; 15: 399-404
107. Carrin GJ, Torfs KE. Economic evaluation of prophylactic treatment with misoprostol in osteoarthritic patients treated with NSAIDs: the case of Belgium. Rev Epidemiol Sante Publique 1990; 38: 187-99
108. Gross PF. Economic impact of new cytoprotective drug on NSAID-induced ulceration [abstract]. Presented at World Congresses of Gastroenterology: 1990 August; Sydney
109. Gabriel SE, Jaakimainen RL, Bombardier C. The cost-effectiveness of misoprostol for nonsteroidal antiimflammatory drug-induced adverse gastrointestinal events. Arthritis Rheum 1993; 36: 447-59
110. Tarricone R, Bertolini F, Saggioro A, et al. Gastropatia da FANS in Italia: valutazione economica della prevenzione con misoprostol. ARGOMENTI di Gastroenterologia Clinica 1994; 7: 263-9
111. Festin HPM, Jacobs JWG, Neyenhuis A, et al. A cost-effectiveness analysis of the use of misoprostol for the prophylaxis of NSAID induced gastric ulcer in the Netherlands [abstract]. Neth J Med 1992; 40 (1, 2): A2
112. Jönsson B, Haglund U. Cost-effectiveness of misoprostol in Sweden [abstract]. Int J Technol Assess Health Care 1992; 8: 234-44